Search results
Results from the WOW.Com Content Network
Sickle cell-beta thalassemia is an inherited blood disorder. The disease may range in severity from being relatively benign and like sickle cell trait to being similar to sickle cell disease . [ 1 ] [ 2 ]
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1] [5] [2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
The DSM-5 criteria puts more emphasis on social or occupational dysfunction than the ICD-10. [7] The ICD-10, on the other hand, puts more emphasis on first-rank symptoms. [2] [8] The current proposal for the ICD-11 criteria for schizophrenia recommends adding self-disorder as a symptom. [9]
Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of both the delta and beta globins. It is generally asymptomatic. [36] There are two clinically significant combinations involving the sickle cell gene: Hemoglobin S/ beta thalassemia: (see above). [35]
Profile of a 10 year old child affected by β thalassemia, illustrating facial abnormalities. Symptoms depend on the type and severity of thalassemia. Carriers of thalassemia genes may have no symptoms (thalassemia minor), very mild symptoms with occasional crisis (thalassemia intermedia) or severe and life threatening symptoms (thalassemia major).
Generally, diseases outlined within the ICD-11 codes 6A20-6A2Z within Mental, behavioural or neurodevelopmental disorders should be included in this category. There are no pages or files in this category.
[10] [11] [12] It was approved in the United States for the treatment of sickle cell disease in December 2023 and for the treatment of transfusion-dependent beta thalassemia in January 2024. [13] [14] [15] Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the ...
Simple-type schizophrenia is a sub-type of schizophrenia included in the International Classification of Diseases , [1] in which it is classified as a mental and behaviour disorder. [2] It is not included in the current Diagnostic and Statistical Manual of Mental Disorders ( DSM-5 ) or the upcoming ICD-11 , [ 3 ] effective 1 January 2022. [ 4 ]